

Nipun B Merchant

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4023653/publications.pdf>

Version: 2024-02-01

48
papers

1,487
citations

430874

18
h-index

330143

37
g-index

48
all docs

48
docs citations

48
times ranked

2464
citing authors

#	ARTICLE	IF	CITATIONS
1	The Miami International Evidence-based Guidelines on Minimally Invasive Pancreas Resection. <i>Annals of Surgery</i> , 2020, 271, 1-14.	4.2	294
2	Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer. <i>Gastroenterology</i> , 2015, 149, 1932-1943.e9.	1.3	151
3	Radiation Therapy for Pancreatic Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. <i>Practical Radiation Oncology</i> , 2019, 9, 322-332.	2.1	121
4	Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer. <i>Annals of Surgery</i> , 2019, 270, 400-413.	4.2	113
5	Pancreatic stellate cell secreted IL-6 stimulates STAT3 dependent invasiveness of pancreatic intraepithelial neoplasia and cancer cells. <i>Oncotarget</i> , 2016, 7, 65982-65992.	1.8	84
6	Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 301-311.	4.1	64
7	Pancreatic Neuroendocrine Tumors (panNETs): Analysis of Overall Survival of Nonsurgical Management Versus Surgical Resection. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 855-866.	1.7	63
8	Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer. <i>Cancer Research</i> , 2018, 78, 6235-6246.	0.9	61
9	Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer. <i>Radiotherapy and Oncology</i> , 2016, 119, 312-318.	0.6	51
10	The Impact of Surgeon Volume on Outcomes After Pancreaticoduodenectomy: a Meta-analysis. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 1723-1731.	1.7	49
11	Adiponectin receptor agonists inhibit leptin induced pSTAT3 and <i>in vivo</i> pancreatic tumor growth. <i>Oncotarget</i> , 2017, 8, 85378-85391.	1.8	45
12	Delayed gastric emptying after pancreaticoduodenectomy. <i>Journal of Surgical Research</i> , 2016, 202, 380-388.	1.6	43
13	Combined Src/EGFR Inhibition Targets STAT3 Signaling and Induces Stromal Remodeling to Improve Survival in Pancreatic Cancer. <i>Molecular Cancer Research</i> , 2020, 18, 623-631.	3.4	32
14	Tobacco Carcinogen-Induced Production of GM-CSF Activates CREB to Promote Pancreatic Cancer. <i>Cancer Research</i> , 2018, 78, 6146-6158.	0.9	30
15	Ipilimumab/Nivolumab Therapy in Patients With Metastatic Pancreatic or Biliary Cancer With Homologous Recombination Deficiency Pathogenic Germline Variants. <i>JAMA Oncology</i> , 2022, 8, 938.	7.1	28
16	Stroma secreted IL6 selects for stem-like population and alters pancreatic tumor microenvironment by reprogramming metabolic pathways. <i>Cell Death and Disease</i> , 2020, 11, 967.	6.3	27
17	Targeting Tumor-Stromal IL6/STAT3 Signaling through IL1 Receptor Inhibition in Pancreatic Cancer. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2280-2290.	4.1	23
18	Racial and ethnic disparities in a statewide registry of patients with pancreatic cancer and an exploratory investigation of cancer cachexia as a contributor to observed inequities. <i>Cancer Medicine</i> , 2019, 8, 3314-3324.	2.8	21

#	ARTICLE	IF	CITATIONS
19	Patterns of National Institutes of Health Grant Funding to Surgical Research and Scholarly Productivity in the United States. <i>Annals of Surgery</i> , 2020, 272, 539-546.	4.2	19
20	Increased MTH1-specific 8-oxodGTPase activity is a hallmark of cancer in colon, lung and pancreatic tissue. <i>DNA Repair</i> , 2019, 83, 102644.	2.8	18
21	Combined Blockade of MEK and CDK4/6 Pathways Induces Senescence to Improve Survival in Pancreatic Ductal Adenocarcinoma. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1246-1256.	4.1	18
22	A Call for Caution in Overinterpreting Exceptional Outcomes After Radical Surgery for Pancreatic Cancer. <i>Annals of Surgery</i> , 2021, 274, e82-e84.	4.2	14
23	Src kinase inhibition restores E-cadherin expression in dasatinib-sensitive pancreatic cancer cells. <i>Oncotarget</i> , 2019, 10, 1056-1069.	1.8	10
24	Obesity enriches for tumor protective microbial metabolites and treatment refractory cells to confer therapy resistance in PDAC. <i>Gut Microbes</i> , 2022, 14, .	9.8	10
25	Cyst location and presence of high grade dysplasia or invasive cancer in intraductal papillary mucinous neoplasms of the pancreas: a seven institution study from the central pancreas consortium. <i>Hpb</i> , 2019, 21, 482-488.	0.3	9
26	Minimally Invasive Surgery is Associated with an Increased Risk of Postoperative Venous Thromboembolism After Distal Pancreatectomy. <i>Annals of Surgical Oncology</i> , 2020, 27, 2498-2505.	1.5	9
27	Surgical management of hepatocellular carcinoma patients with portal vein thrombosis: The United States Safety Net and Academic Center Collaborative Analysis. <i>Journal of Surgical Oncology</i> , 2021, 123, 407-415.	1.7	8
28	Contemporary Reappraisal of Intraoperative Neck Margin Assessment During Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma. <i>JAMA Surgery</i> , 2021, 156, 489.	4.3	8
29	Disparities in Presentation at Time of Hepatocellular Carcinoma Diagnosis: A United States Safety-Net Collaborative Study. <i>Annals of Surgical Oncology</i> , 2021, 28, 1929-1936.	1.5	7
30	Survival inequity in vulnerable populations with early-stage hepatocellular carcinoma: a United States safety-net collaborative analysis. <i>Hpb</i> , 2021, 23, 868-876.	0.3	7
31	Neoadjuvant Therapy. <i>Advances in Surgery</i> , 2020, 54, 49-68.	1.3	5
32	National Institutes of Health Research Funding to Academic Surgical Oncologists: Who Are We and Where Do We Stand?. <i>Annals of Surgical Oncology</i> , 2021, 28, 4195-4202.	1.5	5
33	National Institutes of Health Career Development (K) Awards to Young Surgeons. <i>Annals of Surgery</i> , 2021, 274, 549-555.	4.2	5
34	Ras-p53 genomic cooperativity as a model to investigate mechanisms of innate immune regulation in gastrointestinal cancers. <i>Oncotarget</i> , 2021, 12, 2104-2110.	1.8	5
35	Landmark Series: Importance of Pancreatic Resection Margins. <i>Annals of Surgical Oncology</i> , 2022, 29, 1542-1550.	1.5	5
36	Pre-procedural screening for COVID-19 with nasopharyngeal polymerase chain reaction testing. <i>British Journal of Anaesthesia</i> , 2020, 125, e422-e424.	3.4	4

#	ARTICLE	IF	CITATIONS
37	Multimodality Therapy in Operable Pancreatic Cancer: Should We Sequence Surgery Last?. <i>Annals of Surgical Oncology</i> , 2021, 28, 1884-1886.	1.5	4
38	Deciphering high risk molecular alterations in gastrointestinal malignancy utilizing an extreme outlier strategy. <i>Oncoscience</i> , 2020, 7, 26-29.	2.2	4
39	Intraoperative Pancreatic Neck Margin Assessment During Pancreaticoduodenectomy for Pancreatic Adenocarcinoma in the Era of Neoadjuvant Therapy: A Multi-institutional Analysis from the Central Pancreatic Consortium. <i>Annals of Surgical Oncology</i> , 2022, 29, 6004-6012.	1.5	4
40	Utility of Radiation After Neoadjuvant Chemotherapy for Surgically Resectable Esophageal Cancer. <i>Annals of Surgical Oncology</i> , 2020, 27, 662-670.	1.5	2
41	A Novel Interdisciplinary Iterative Approach for Optimizing the Electronic Health Record to Improve Perioperative Efficiency. <i>Annals of Surgery</i> , 2020, Publish Ahead of Print, 669-675.	4.2	2
42	Attrition during neoadjuvant chemotherapy for gastric adenocarcinoma is associated with decreased survival: A United States Safetyâ€Net Collaborative analysis. <i>Journal of Surgical Oncology</i> , 2021, 124, 1317-1328.	1.7	2
43	Interleukin-1 signaling in solid organ malignancies. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2022, 1877, 188670.	7.4	2
44	ASO Author Reflections: Pancreatic Resection Marginsâ€Chasing Moons. <i>Annals of Surgical Oncology</i> , 2022, 29, 1551-1552.	1.5	1
45	ASO Author Reflections: National Institutes of Health Funding to Surgical Oncology Research. <i>Annals of Surgical Oncology</i> , 2021, 28, 4203-4204.	1.5	0
46	Neoadjuvant and adjuvant, floxuridine, leucovorin, oxaliplatin, and docetaxel (FLOD) in patients with locally advanced operable gastroesophageal adenocarcinoma: A phase II study with pathologic responses and long term follow-up.. <i>Journal of Clinical Oncology</i> , 2016, 34, 124-124.	1.6	0
47	ASO Author Reflections: Should we Stick our Neck Out for Pancreatic Neck Margins During Pancreaticoduodenectomy After Neoadjuvant Therapy?. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	0
48	Abstract 1565: Targeting stromal-specific p38 MAPK signaling to stifle inflammatory reprogramming of cancer-associated fibroblasts in pancreatic cancer. <i>Cancer Research</i> , 2022, 82, 1565-1565.	0.9	0